Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2009 1
2019 1
2021 3
2022 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade.
Patel RB, Hernandez R, Carlson P, Grudzinski J, Bates AM, Jagodinsky JC, Erbe A, Marsh IR, Arthur I, Aluicio-Sarduy E, Sriramaneni RN, Jin WJ, Massey C, Rakhmilevich AL, Vail D, Engle JW, Le T, Kim K, Bednarz B, Sondel PM, Weichert J, Morris ZS. Patel RB, et al. Among authors: massey c. Sci Transl Med. 2021 Jul 14;13(602):eabb3631. doi: 10.1126/scitranslmed.abb3631. Sci Transl Med. 2021. PMID: 34261797 Free PMC article.
After combined treatment, 45 to 66% of mice exhibited complete response and tumor-specific T cell memory, compared to 0% with (90)Y-NM600 or ICI alone. This required expression of STING in tumor cells. Combined TRT and ICI activated production of proinflammatory cytokines …
After combined treatment, 45 to 66% of mice exhibited complete response and tumor-specific T cell memory, compared to 0% with (90)Y-N …
UCHL1 is a potential molecular indicator and therapeutic target for neuroendocrine carcinomas.
Liu S, Chai T, Garcia-Marques F, Yin Q, Hsu EC, Shen M, Shaw Toland AM, Bermudez A, Hartono AB, Massey CF, Lee CS, Zheng L, Baron M, Denning CJ, Aslan M, Nguyen HM, Nolley R, Zoubeidi A, Das M, Kunder CA, Howitt BE, Soh HT, Weissman IL, Liss MA, Chin AI, Brooks JD, Corey E, Pitteri SJ, Huang J, Stoyanova T. Liu S, et al. Among authors: massey cf. Cell Rep Med. 2024 Feb 20;5(2):101381. doi: 10.1016/j.xcrm.2023.101381. Epub 2024 Jan 19. Cell Rep Med. 2024. PMID: 38244540 Free PMC article.
The development of Nanosota-1 as anti-SARS-CoV-2 nanobody drug candidates.
Ye G, Gallant J, Zheng J, Massey C, Shi K, Tai W, Odle A, Vickers M, Shang J, Wan Y, Du L, Aihara H, Perlman S, LeBeau A, Li F. Ye G, et al. Among authors: massey c. Elife. 2021 Aug 2;10:e64815. doi: 10.7554/eLife.64815. Elife. 2021. PMID: 34338634 Free PMC article.
(90)Y-NM600 targeted radionuclide therapy induces immunologic memory in syngeneic models of T-cell Non-Hodgkin's Lymphoma.
Hernandez R, Walker KL, Grudzinski JJ, Aluicio-Sarduy E, Patel R, Zahm CD, Pinchuk AN, Massey CF, Bitton AN, Brown RJ, Sondel PM, Morris ZS, Engle JW, Capitini CM, Weichert JP. Hernandez R, et al. Among authors: massey cf. Commun Biol. 2019 Feb 26;2:79. doi: 10.1038/s42003-019-0327-4. eCollection 2019. Commun Biol. 2019. PMID: 30820474 Free PMC article.
Finding improved therapeutic strategies against T-cell Non-Hodgkin's Lymphoma (NHL) remains an unmet clinical need. We implemented a theranostic approach employing a tumor-targeting alkylphosphocholine (NM600) radiolabeled with (86)Y for positron emission tomography (PET) …
Finding improved therapeutic strategies against T-cell Non-Hodgkin's Lymphoma (NHL) remains an unmet clinical need. We implemented a …
Antitumor efficacy of (90)Y-NM600 targeted radionuclide therapy and PD-1 blockade is limited by regulatory T cells in murine prostate tumors.
Potluri HK, Ferreira CA, Grudzinski J, Massey C, Aluicio-Sarduy E, Engle JW, Kwon O, Marsh IR, Bednarz BP, Hernandez R, Weichert JP, McNeel DG. Potluri HK, et al. Among authors: massey c. J Immunother Cancer. 2022 Aug;10(8):e005060. doi: 10.1136/jitc-2022-005060. J Immunother Cancer. 2022. PMID: 36002185 Free PMC article.
TRT had multiple effects on the tumor microenvironment including increasing CD8 +T cell infiltration, increasing checkpoint molecule expression on CD8 +T cells, and increasing PD-L1 expression on myeloid cells. ...Tregs remained functional up to 1 week following TRT …
TRT had multiple effects on the tumor microenvironment including increasing CD8 +T cell infiltration, increasing checkpoint molecule …
Hidden morbidity with "successful" early discharge.
Radmacher P, Massey C, Adamkin D. Radmacher P, et al. Among authors: massey c. J Perinatol. 2002 Jan;22(1):15-20. doi: 10.1038/sj.jp.7210586. J Perinatol. 2002. PMID: 11840237